PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction<em>: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer</em>
AID  - 10.1136/jitc-2020-001622corr1
DP  - 2021 Feb 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - 1--1
VI  - 9
IP  - 2
4099  - http://jitc.bmj.com/content/9/2/1.short
4100  - http://jitc.bmj.com/content/9/2/1.full
SO  - J Immunother Cancer2021 Feb 01; 9